TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $791,894 | -13.6% | 102,710 | +0.8% | 0.00% | 0.0% |
| Q4 2023 | $916,476 | +66.3% | 101,944 | +65.4% | 0.00% | 0.0% |
| Q3 2023 | $550,954 | -58.6% | 61,628 | -28.9% | 0.00% | 0.0% |
| Q2 2023 | $1,331,358 | +10.3% | 86,677 | +61.5% | 0.00% | 0.0% |
| Q1 2023 | $1,206,858 | +26.7% | 53,662 | +18.4% | 0.00% | 0.0% |
| Q4 2022 | $952,890 | -17.3% | 45,311 | -3.1% | 0.00% | 0.0% |
| Q3 2022 | $1,152,000 | +12.7% | 46,755 | +10.8% | 0.00% | 0.0% |
| Q2 2022 | $1,022,000 | -12.1% | 42,181 | -6.6% | 0.00% | 0.0% |
| Q1 2022 | $1,163,000 | -18.8% | 45,154 | -2.1% | 0.00% | 0.0% |
| Q4 2021 | $1,433,000 | +47.7% | 46,124 | +15.4% | 0.00% | 0.0% |
| Q3 2021 | $970,000 | +101.2% | 39,952 | +20.8% | 0.00% | – |
| Q2 2021 | $482,000 | -45.8% | 33,075 | -7.1% | 0.00% | – |
| Q1 2021 | $889,000 | -46.4% | 35,593 | -41.6% | 0.00% | -100.0% |
| Q4 2020 | $1,660,000 | – | 60,909 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |